Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg, C Sederholm… - European journal of …, 2011 - Elsevier
Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - European Journal of …, 2011 - europepmc.org
Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
[引用][C] Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the …
A KOCH, B BERGMAN, E HOLMBERG… - European journal of …, 2011 - pascal-francis.inist.fr
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A
double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung …
double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - … Journal of Cancer, 2011 - portal.research.lu.se
Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - European Journal of …, 2011 - ejcancer.com
Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg, C Sederholm… - European Journal of …, 2011 - infona.pl
Increased expression of cyclooxygenase-2 (COX-2) is common in non-small cell lung
cancer (NSCLC) and has been associated with poor prognosis. Experimental and clinical …
cancer (NSCLC) and has been associated with poor prognosis. Experimental and clinical …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - … journal of cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
[HTML][HTML] Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the …
A Koch, B Bergman, E Holmberg… - European Journal of …, 2011 - diva-portal.org
BACKGROUND: Increased expression of cyclooxygenase-2 (COX-2) is common in non-
small cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental …
small cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - European Journal of …, 2011 - lup.lub.lu.se
Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish …
A Koch, B Bergman, E Holmberg… - European Journal of …, 2011 - diva-portal.org
Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …